Thursday, November 17, 2011

Agreement With Innocoll for Surgical Adhesion Barrier CollaGUARD

TORONTO, ONTARIO, Nov 14, 2011 (MARKETWIRE via COMTEX) -- Envoy Capital Group Inc. /quotes/zigman/38441 CA:ECG +8.46% /quotes/zigman/38429/quotes/nls/ecgi ECGI +0.94% ("Envoy") announces that Merus Labs International Inc. (cnsx:MR) ("Merus") has entered into a License and Distribution Agreement with Innocoll in Canada for CollaGUARD surgical adhesion barrier for the prevention of postoperative adhesions following abdominal and pelvic surgery. Envoy and Merus Labs have agreed to amalgamate subject to shareholder and regulatory approval as earlier announced. Meetings of shareholder of Envoy and Merus have been scheduled for December 9, 2011.

"Adhesions occur after most surgical procedures, and are of major clinical, social and economic concern. The addition of CollaGUARD to our portfolio means that thousands of patients at risk of adhesion will have a clinically proven superior solution. We look forward to obtaining Health Canada approval and the launch of CollaGUARD in 2012." said Ali Moghaddam, Vice President at Merus Labs.

Dr. Michael Myers, President and CEO of Innocoll stated, "We are pleased to announce the expansion of our partnership with Merus to include CollaGUARD and we look forward to the successful launch of the product in Canada."

About CollaGUARD(R)

CollaGUARD is a transparent bioresorbable film of 100% type I collagen developed using Innocoll's proprietary CollaFilm technology. It is approved in Europe for the prevention of postoperative adhesions in patients undergoing abdominopelvic laparotomy or laparoscopy. When tested in vivo, CollaGUARD increased the probability of remaining adhesion-free by more than six fold (P less than 0.001) and significantly reduced the extent and severity of adhesions (P less than 0.001).

CollaGUARD has been designed and engineered with a unique combination of features for optimal handling, ease-of-use, and antiadhesion performance. It is highly stable at room temperature and does not require any advanced preparation before use. The product is non-tacky and can be easily rolled for insertion through a trocar when implanted laparoscopically. CollaGUARD is available in a wide variety of sizes up to 20 x 30 cm; it may be cut and sutured if required and therefore used efficiently across a broad range of surgeries.

About Innocoll, Inc.

Innocoll is a privately held, biopharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. The company develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx(R), CollaFilm, DermaSil(TM), CollaPress(TM) and Liquicoll(R). Approved products based on the Company's technologies include: Collatamp(R) G, Septocoll(R), CollaGUARD, Collieva(R), CollaCare(R), Collexa(R), Zorpreva(TM), and LidoColl(R).

Other products in clinical and regulatory development include: CollaRx Gentamicin Surgical Implant in phase 3 for prevention of surgical wound infections, Cogenzia in phase 3 for the adjuvant treatment of infected diabetic foot ulcers, and Xaracoll in phase 2b for the management of post-operative pain. For more information, please visit .
Read More :

No comments: